FDA
-
-
-
-
-
-
-
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
-
-
-
-
-
-
-
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
-
-
-
-
-
-
-
Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
-
-
-
-
-
-
-
Vitality Biopharma Appoints Former Ohio Governor Richard F. Celeste to Board
-
-
-
-
-
-
-
Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease
-
-
-
-
326,688 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

